CARDURA XL Drug Patent Profile

Which patents cover Cardura Xl, and what generic alternatives are available?

Cardura Xl is a drug marketed by Viatris and is included in one NDA.

The generic ingredient in CARDURA XL is doxazosin mesylate. There are fourteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cardura Xl

A generic version of CARDURA XL was approved as doxazosin mesylate by APOTEX on October 18^th, 2000.

Summary for CARDURA XL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	106
Clinical Trials:	11
Patent Applications:	2,094
Drug Prices:	Drug price information for CARDURA XL
DailyMed Link:	CARDURA XL at DailyMed

See drug prices for CARDURA XL

See drug sales revenues for CARDURA XL

Recent Clinical Trials for CARDURA XL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The University of Texas Health Science Center, Houston	Phase 1
Brown University	Phase 2
University of California, Los Angeles	Phase 3

See all CARDURA XL clinical trials

Pharmacology for CARDURA XL

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

US Patents and Regulatory Information for CARDURA XL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	CARDURA XL	doxazosin mesylate	TABLET, EXTENDED RELEASE;ORAL	021269-001	Feb 22, 2005		RX	Yes	No
Viatris	CARDURA XL	doxazosin mesylate	TABLET, EXTENDED RELEASE;ORAL	021269-002	Feb 22, 2005		RX	Yes	Yes

Expired US Patents for CARDURA XL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	CARDURA XL	doxazosin mesylate	TABLET, EXTENDED RELEASE;ORAL	021269-002	Feb 22, 2005

International Patents for CARDURA XL

See the table below for patents covering CARDURA XL around the world.

Country	Patent Number	Title	Estimated Expiration
Ireland	62131	Dosage form for dispensing drug for human therapy
Japan	H01242528	PERMEABLE ADMINISTRATION FORM
Portugal	90049	FORMA DE DOSAGEM PARA ADMINISTRAR UM MEDICAMENTO PARA TERAPIA HUMANA
Denmark	135389
Austria	96308
European Patent Office	0334465	Dispositif pour doser un médicament pour la thérapie humaine. (Dosage form for dispensing drug for human therapy.)

Market dynamics and financial trajectory for CARDURA XL (doxazosin extended-release)

Last updated: April 26, 2026

CARDURA XL (doxazosin extended-release) is a long-standing, once-daily alpha-1 blocker marketed for benign prostatic hyperplasia (BPH). Its commercial trajectory has been shaped by (1) end-market penetration in BPH, (2) competitive pricing pressure from other BPH classes and generics, and (3) the cost and throughput realities of operating a legacy brand once generic erosion has set in.

Core market role

• Drug class: alpha-1 adrenergic blocker (extended-release formulation)
• Primary indication: BPH (symptomatic management, including reduction of urinary symptoms)
• Formulation: extended-release, once daily (CARDURA XL)

What is CARDURA XL’s product and market position in BPH?

CARDURA XL is positioned in the BPH symptomatic-treatment segment alongside alpha-1 blockers (e.g., tamsulosin, alfuzosin, silodosin), 5-alpha-reductase inhibitors (finasteride, dutasteride), and combination regimens. In practice, the segment splits between:

• “Fast symptom relief” therapy choices that target alpha-1 receptors
• “Disease modification” or “future progression risk” choices led by 5-alpha-reductase inhibitors
• Combination strategies for patients with higher-risk features

CARDURA XL competes most directly with:

• Other alpha-1 blockers with different receptor selectivity and dosing convenience
• Generic doxazosin and other generics within the alpha-1 class

Because BPH is a chronic, high-prevalence condition in the male population, the market supports long-term therapy use. But legacy oral brands are particularly exposed once generics reach broad coverage and payers move to preferred, lower-cost options.

How do market dynamics constrain CARDURA XL pricing and growth?

CARDURA XL’s market dynamics are dominated by typical “legacy oral small molecule” constraints:

1) Generic erosion and payer preference

When generics enter, pharmacy benefit managers and formularies typically steer utilization toward the lowest-cost therapeutically equivalent options. For CARDURA XL, this creates a sustained pressure chain:

• Higher out-of-pocket cost for non-preferred coverage
• Switch behavior toward lower-cost equivalents within the alpha-1 class
• Lower net price due to rebates and formulary mechanics

2) Class competition inside alpha-1 blockers

Alpha-1 blocker competition has shifted toward agents with:

• Uroselectivity profiles (where applicable) that can reduce certain adverse effects
• Fixed dosing and established prescriber preference patterns
• Broad generic availability (for many competitors as well)

This reduces the ability for a legacy extended-release brand to expand share based on incremental clinical differentiation alone.

3) Utilization remains “treatment intensity limited”

BPH treatment is largely driven by symptom burden, patient tolerability, and prescriber selection. Once a patient is stable on a generic-equivalent alpha-1 blocker option, switching friction can be low for payers but meaningful for patients already responding. That dynamic caps re-acceleration potential for branded extended-release products.

4) Net sales are structurally sensitive to contracting

For older brands, revenue is more sensitive to:

• Rebates
• Contracting terms with managed care
• Channel inventory timing than to unit growth alone

What is CARDURA XL’s financial trajectory and how is it measured?

For legacy brands, “financial trajectory” is typically evaluated through:

• Annual net sales trend (brand-level)
• Gross-to-net changes driven by rebates, chargebacks, and discounts
• Prescription volumes and share of voice in BPH
• Share loss versus preferred generics and class alternatives

However, the name CARDURA XL is widely used as a brand label while accounting is usually captured under specific product identifiers in company filings. Without the brand’s reported net sales series in the sources provided here, the only rigorous “financial trajectory” statement that can be made is directional: legacy oral brands in this category tend to show prolonged decline after generic penetration, followed by stabilization at lower net sales levels (often with periodic step-changes from formulary and contracting cycles).

How does CARDURA XL compare with other BPH options on competitive economics?

Below is a practical competitive lens for revenue and share dynamics, focused on how payers and patients make selection decisions.

Treatment segment in BPH	Typical payer behavior	Revenue implication for a legacy branded alpha-1 blocker
Alpha-1 blockers (broad equivalents)	Prefer low-cost agents under step edits and tiering	Net price compression and share erosion after generics
5-alpha-reductase inhibitors	Use for patients with risk features; payers may cover at scale	Potential for substitution away from alpha-1-only strategies
Combination therapy	Used when symptom control plus risk reduction is needed	Less headroom for alpha-1 extended-release brand-only share gain

CARDURA XL’s position is most exposed where payer policy favors “lowest acquisition cost alpha-1 blocker,” which is common once multiple therapeutically equivalent generics are available.

What events usually shift trajectory for CARDURA XL-type products?

In this market, the main swing factors are not clinical but commercial and operational:

• Formulary redesigns: moving doxazosin ER to non-preferred tiers or applying utilization management
• PBM contracting changes: better discounts for competing generics
• Generic entry timing: direct step down in net price and market share
• Channel inventory cycles: short-term revenue volatility even when demand is flat
• Switching patterns: prescriber behavior and patient willingness to change

What does “extended-release” change in market dynamics?

Extended-release formulations can improve dosing convenience and tolerability for some patients, but in a chronic BPH setting, the market advantage usually narrows after generic equivalents reach prevalence and when payers can achieve similar outcomes with lower-cost options.

For CARDURA XL specifically, “extended-release” is a differentiator at the patient level, but payer economics still tend to dominate once therapeutic alternatives are widely available.

How should investors and business planners underwrite CARDURA XL risk and downside?

Underwriting a legacy branded BPH oral asset should model:

• Net sales decay curve driven by contracting and generic substitution
• Share baseline that is “sticky but bounded,” meaning it persists while patients tolerate therapy, then gradually erodes
• Rebate and discount intensification as competitors deepen preferred positioning

A conservative planning view typically assumes:

• Continued decline in net price toward a lower long-run average as contracting ratchets down
• Unit volume stabilization at reduced levels after major formulary switches
• Limited upside unless payer strategy or distribution changes reverse entrenched tiering

What are the key business implications for R&D and licensing decisions?

CARDURA XL’s market dynamics imply that incremental lifecycle innovation in a mature class must overcome payer-driven economics. For a next-generation BPH asset or a lifecycle extension program, the credible levers are:

• Strong differentiation that changes prescriber behavior and payer coverage (not only dosing convenience)
• Evidence that shifts utilization toward the product under payer criteria
• Target populations where competition is weaker or where clinicians see clear outcome tradeoffs

Key Takeaways

• CARDURA XL sits in the mature BPH alpha-1 blocker market, where generic availability and payer preference drive sustained pricing and share pressure.
• Extended-release formulation can support tolerability and dosing convenience, but payer economics usually dominate after generic penetration.
• The financial trajectory for this product class typically follows decline after generics, with stabilization at lower net sales levels and periodic contracting-driven volatility.
• Commercial underwriting should focus on net price compression, formulary tier movement, and rebate dynamics rather than expecting unit growth inflection in a mature class.

FAQs

1) What indication does CARDURA XL serve?
CARDURA XL is marketed for symptomatic treatment of benign prostatic hyperplasia (BPH).

2) What drug class is CARDURA XL in the BPH market?
It is an alpha-1 adrenergic blocker (extended-release).

3) What typically happens to branded BPH oral medicines after generic entry?
They typically face sustained net price compression and share erosion due to payer tiering and therapeutic substitution.

4) Why does “extended-release” not fully protect CARDURA XL revenue?
Because payer coverage decisions and acquisition-cost incentives often override formulation-level differentiation once generics are available.

5) What commercial variables most affect legacy brand performance?
Formulary status, PBM contracting terms (rebates and discounts), and channel inventory cycles.

---

References

No external sources were provided in the prompt for CARDURA XL’s brand-level financials, annual net sales, or prescription volumes; therefore, no citations are included.